ESMO 2022 | Breast cancer trials of interest at ESMO 2022

Sara Tolaney, MD, MPH, Dana Farber Cancer Institute, Boston, MA, comments on her highlights in the field of breast cancer presented at the European Society for Medical Oncology (ESMO) 2022 Congress, including developments in antibody-drug conjugates (ADCs). The Phase III TROPiCS-02 trial (NCT03901339) of sacituzumab govitecan demonstrated favorable overall survival (OS) in patients with HR-positive, HER2-negative breast cancer. OS data from the Phase III MONARCH 3 (NCT02246621) trial of abemaciclib was additionally presented, providing clarity in which CDK4/6 inhibitors, especially after PALOMA-2 trial (NCT01740427) of palbociclib. This interview took place at the ESMO 2022 Congress in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.